DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-200-0200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.03 billion
Profitability
Miscellaneous
Employees2,800
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
DexCom (NASDAQ:DXCM) Frequently Asked Questions
What is DexCom's stock symbol?
DexCom trades on the NASDAQ under the ticker symbol "DXCM."
How were DexCom's earnings last quarter?
DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings data on Wednesday, May, 1st. The medical device company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.12. The medical device company had revenue of $280.50 million for the quarter, compared to analysts' expectations of $246.10 million. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The business's quarterly revenue was up 52.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.30) EPS. View DexCom's Earnings History.
When is DexCom's next earnings date?
What price target have analysts set for DXCM?
16 brokers have issued twelve-month price objectives for DexCom's stock. Their forecasts range from $125.00 to $175.00. On average, they anticipate DexCom's stock price to reach $153.20 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price. View Analyst Price Targets for DexCom.
What is the consensus analysts' recommendation for DexCom?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.
What are Wall Street analysts saying about DexCom stock?
Here are some recent quotes from research analysts about DexCom stock:
- 1. According to Zacks Investment Research, "DexCom exited the first quarter on a strong note, wherein both the top and bottom line beat the Zacks Consensus Estimate. Impressive contributions from the Sensor, Transmitter and Receiver segments were key catalysts. A strong guidance also instills investor optimism. The glucose monitoring market presents significant commercial opportunity for DexCom. The company’s opportunities in alternative markets such as the non-intensive diabetes management space, hospital, gestational, pre-diabetes and obesity are likely to provide it a competitive edge in the MedTech space. Shares of the company have outperformed the industry in a year’s time. Meanwhile, cutthroat competition in the market for blood & glucose monitoring devices remains a headwind. We believe that the company’s margins will continue to remain under pressure in the upcoming quarters, owing to high product development costs and rising expenditures on the R&D front." (5/6/2019)
- 2. Stephens analysts commented, "We rate uniQure Overweight. uniQure focuses on the development of gene therapy products for patients suffering from severe genetic diseases. uniQure is in Phase 3 development for the treatment of hemophilia B with AMT-061, and has additional preclinical programs for Huntington’s disease, hemophilia A and cardiovascular disease." (8/23/2018)
Has DexCom been receiving favorable news coverage?
News stories about DXCM stock have been trending somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. DexCom earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are some of DexCom's key competitors?
Some companies that are related to DexCom include Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), ABIOMED (ABMD), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Novocure (NVCR), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM) and NuVasive (NUVA).
What other stocks do shareholders of DexCom own?
Who are DexCom's key executives?
DexCom's management team includes the folowing people:
- Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
- Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
- Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
- Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
- Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)
Who are DexCom's major shareholders?
DexCom's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.40%), Janus Henderson Group PLC (1.60%), Renaissance Technologies LLC (1.39%), Wellington Management Group LLP (1.28%), Artisan Partners Limited Partnership (1.28%) and Geode Capital Management LLC (1.22%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.
Which institutional investors are selling DexCom stock?
DXCM stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, William Blair Investment Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, TimesSquare Capital Management LLC, Westfield Capital Management Co. LP, Rockefeller Capital Management L.P., Broadfin Capital LLC and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for DexCom.
Which institutional investors are buying DexCom stock?
DXCM stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Renaissance Technologies LLC, Janus Henderson Group PLC, Goldman Sachs Group Inc., AQR Capital Management LLC, Pennsylvania Trust Co, Pennsylvania Trust Co and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for DexCom.
How do I buy shares of DexCom?
Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DexCom's stock price today?
One share of DXCM stock can currently be purchased for approximately $118.04.
How big of a company is DexCom?
DexCom has a market capitalization of $10.75 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.
What is DexCom's official website?
How can I contact DexCom?
DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]
MarketBeat Community Rating for DexCom (NASDAQ DXCM)
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
